Finance entity
markets accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Of the tracked stories, 1 of 3 also mention Bank of America, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline.
Last mentioned: Aug 17, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Of the tracked stories, 1 of 3 also mention Bank of America, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline. Across a 39-day span, the pace is roughly 0.5 stories per week. The 5 average consequence score is below the beat benchmark of 5.9 in the same window. This profile follows 3 Finance stories mentioning The Goldman Sachs Group across the period from July 10, 2026 to August 17, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 810 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering The Goldman Sachs Group. Shared-story counts are live from our verified record — not editorial picks.
Mitsubishi UFJ's Q2 13F shows a 22.3% reduction in Nike and 6.4% in Zoetis, just as sell-side targets on NKE cluster at $42–$47. For finance professionals, the filings highlight institutional rebalancing, ownership concentration, and analyst caution as key sentiment signals.
Source: Ticker Report · Watch List News
Globant reported EPS of $1.40, missing consensus by $0.10, while revenue of $614.42 million slightly beat estimates but was flat year over year. Shares fell 8.9% to $37.35 as analysts lowered price targets. The company reiterated FY2026 EPS guidance of $5.75-$6.15 and Q3 guidance of $1.43.
Source: themarketsdaily.com · dailypolitical.com
Wells Fargo’s $225 target is the lowest among major banks, yet ResMed’s average analyst target of $270.64 implies a 23.2% upside. Markets weigh defensive balance sheet qualities against emerging therapeutic competition.
The Goldman Sachs Group is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
